Key Drivers
- Strong liquidity
- High gross margins
- Negative equity/debt
AIAI Summary
Ultragenyx has shifted from a high‑burn, long‑shot pipeline biotech into a commercialization-plus-monetization story where valuation now hinges on a few near‑term binary catalysts (UX111 CMC resubmission timing, GTX‑102/UX143 readouts) and finite royalty/PRV proceeds rather than broad pipeline optionality; monitor UX111 CMC remediation progress, scheduled royalty/PRV receipts, and cash runway (need for refinancing or dilution) as the decisive drivers of upside or rapid de‑rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •High gross margins
- •Negative equity/debt
Rare has strong liquidity and very high gross margins but remains deeply unprofitable with heavy opex, negative equity, large debt and sustained negative free cash flow, relying on external financing to operate.
Price Behavior
Key Price Behavior Insights:
- •Mild short-term downtrend
- •Momentum neutral
- •Near-term support intact
Price is slightly below its last month SMA (~$22.10) with neutral-to-mild bullish momentum (RSI ~62), nearest downside at $20.18–$20.52 and layered resistance at $23.4–$23.9 and $24.7–$24.8.
Price traded slightly below last month
Sentiment & News
Key News Insights:
- •Coordinated law‑firms
- •Phase III failure
- •April 6 deadline
Multiple law firms are soliciting Ultragenyx investors in a securities class action over alleged misstatements about setrusumab following a reported Phase III failure and >42% stock drop, with an April 6 lead-plaintiff deadline.
The concentrated plaintiff outreach and litigation risk will likely sustain stock volatility and pressure investor sentiment until legal outcomes or company disclosures clarify exposure
Similar Companies in Healthcare
Other companies in the same sector with AI ratings